CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395 | +44 (0) 20 3951 8071
info@oxonepi.com

Meet with OXON at CTS 2024

Meet OXON at CTS

November 28-29 | Barcelona | Booth #E3

OXON is a leading provider of global data collection and Real-World Evidence (RWE) studies and integrated evidence strategy across major therapeutic areas, orphan conditions, pregnancy, and vaccines, for Clinical Development, Safety, and Market Access.

We invite you to visit us at the 9th Annual Clinical Trial Summit (CTS) in Barcelona this week, Booth #E3. Our team is eager to discuss how our RWE-driven services and new developments can support your clinical research needs.

At CTS 2024, we will also showcase our capabilities to help biotech and pharma companies optimize drug development across all phases (I-IV). Our team has co-authored over 100 publications in leading journals like NEJM and Lancet and is implementing the groundbreaking FDA/EMA-approved Win Ratio methodology.

This innovation enhances trial power and efficiency, particularly in rare diseases and early-phase studies.

    SUBMIT TO SCHEDULE YOUR MEETING AT CTS 2024:

    Your details: Fields marked with an asterisk (*) are required.

    Company/Organization name *

    Technical Area *

    First name*

    Lastname*

    Position/Job Title*

    Work Email address*

    Phone number

    Country*

    What would you like to discuss during the meeting?*

    As responsible for the processing of the personal data you provide, OXON informs you that your data will be processed in accordance with the provisions of the laws in force related to data protection and notably the General Data Protection Regulation 2016/679. Your data will be used to establish or maintain a business relationship and sending you communications about our services. The data will be kept as long as there is a legitimate interest. As a data subject, you will have the right to withdraw your consent at any time. You will also have the right to access, to rectify, to erase your personal data as well as the right to ask for its portability or the limitation of its processing.



    © 2024 All rights reserved.